S-1: Femasys Launches Public Offering Amid Nasdaq Delisting Threat

Femasys Inc. files S-1 for a public offering of 11.4 million shares to raise capital, while facing imminent delisting from Nasdaq due to low market value and bid price.

Summary

• Femasys Inc. is offering 11,428,571 shares of its common stock, listed on the Nasdaq Capital Market under the symbol FEMY.
• The last reported sale price of the common stock on Nasdaq was $0.70 per share as of August 18, 2025.
• The company expects to receive estimated net proceeds of $7.2 million from this offering, or $8.3 million if the underwriters exercise their option to purchase additional shares.
• Proceeds are intended for product development, general corporate purposes, capital expenditures, working capital, general and administrative expenses, and potential acquisitions.
• Femasys received a Nasdaq delisting notice on May 19, 2025, for failing to meet the minimum $35.0 million Market Value of Listed Securities (MVLS) requirement, with a deadline of November 17, 2025, to regain compliance.
• The company also received a Nasdaq notice on July 16, 2025, for failing to meet the minimum $1.00 bid price requirement, with a deadline of January 12, 2026, to regain compliance.
• As of June 30, 2025, Femasys had cash and cash equivalents of approximately $3.2 million and convertible notes payable of approximately $6.1 million.
• The company's net tangible book value was approximately $1.5 million, or $0.04 per share, as of June 30, 2025.
• The offering will result in an immediate dilution of approximately $0.50 per share to new investors.
• Femasys is a biomedical innovator in women's health with products like FemaSeed (infertility), FemVue (fallopian tube diagnostic), FemCerv (cervical cancer diagnosis), and FemBloc (permanent birth control).
• FemBloc received CE mark certification in the EU in March 2025 (delivery system) and June 2025 (blended polymer component), and its pivotal clinical trial for U.S. approval is currently enrolling participants.
• The company entered into an Equity Line of Credit with Alumni Capital LP on June 30, 2025, for up to $10 million in common stock sales through December 31, 2026.
• In May 2025, Femasys completed an underwritten public offering and a private placement, raising gross proceeds of $4.5 million.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant financial distress, including a 'going concern' warning from auditors and two active Nasdaq delisting notices. While the capital raise provides some liquidity, it comes with substantial dilution for new investors and highlights the company's precarious financial position. Product approvals are positive, but overshadowed by operational and listing risks.

Positives

• Femasys has a broad patent-protected portfolio of therapeutic and diagnostic products for women's health, with over 200 issued patents globally.
• Key products like FemaSeed and FemVue have received global regulatory approvals and are being commercialized in the U.S. and international markets.
• FemBloc, a non-surgical permanent birth control solution, received CE mark certification in the EU in March and June 2025, marking its first global regulatory approval.
• Positive data from initial clinical trials of FemBloc demonstrated compelling effectiveness and five-year safety.
• The company has established strategic distribution partnerships for FemBloc in Spain.
• The current offering aims to raise significant capital (estimated $7.2 million net proceeds) to fund product development and operations.

Negatives

• Femasys received a Nasdaq delisting notice on May 19, 2025, for failing to meet the minimum $35.0 million Market Value of Listed Securities (MVLS) requirement.
• The company also failed to meet alternative Nasdaq listing standards of $2.5 million stockholders' equity or $500,000 net income.
• A second Nasdaq notice was received on July 16, 2025, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
• The auditor's report for December 31, 2024, includes an explanatory paragraph stating that recurring losses from operations and net capital deficiency raise substantial doubt about the company's ability to continue as a going concern.
• The company has convertible notes maturing in November 2025, which could pose a liquidity challenge if not converted.
• New investors in this offering will experience immediate and substantial dilution of $0.50 per share.
• The company's stock price has been, and is expected to remain, highly volatile.

Risks

• Ability to obtain additional financing to fund commercialization and operations.
• Ability to obtain additional financing for U.S. clinical development of FemBloc.
• Ability to pay convertible notes due November 2025 if not converted.
• Ability to obtain U.S. FDA approval for FemBloc.
• Ability to successfully grow sales of FemaSeed in the U.S. and FemBloc in the EU.
• Accuracy of estimates regarding the total addressable market for products.
• Competition from other companies and technologies in the industry.
• Commercial success and market acceptance of products and product candidates.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for products.
• Ability to accurately forecast customer demand and manage inventory.
• Ability to build, manage, and maintain direct sales and marketing organization.
• Ability to establish, maintain, grow, or increase sales and revenues.
• Ability to continue operating as a going concern.
• Clinical trial outcomes, including demonstrating safety and effectiveness and timely subject enrollment.
• Manufacturing compliance with laws and regulations, and oversight of third-party suppliers.
• Ability to hire and retain senior management and other highly qualified personnel.
• Impact of FDA or other U.S. or foreign regulatory actions, including healthcare reform.
• Timing or likelihood of regulatory filings and approvals or clearances.
• Ability to establish and maintain intellectual property protection and avoid infringement claims.
• Volatility of the common stock trading price.
• Potential for future dilution from equity offerings.
• Sales of substantial amounts of common stock by existing stockholders, directors, or officers post-offering.
• Risk of delisting from Nasdaq due to non-compliance with MVLS and minimum bid price requirements.

Future Outlook

The company intends to use the net proceeds from this offering for product development, general corporate purposes, capital expenditures, working capital, general and administrative expenses, and potentially for acquisitions or investments in complementary businesses, products, and technologies. Management is actively monitoring the Nasdaq listing requirements and considering options, including a reverse stock split, to regain compliance with the minimum bid price and market value requirements. The company's ability to continue as a going concern is dependent on its ability to obtain additional financing and achieve profitability.

Management Comments

• We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split.
• We intend to actively monitor the MVLS of our common stock between now and November 17, 2025, and will consider our available options to regain compliance with the Minimum MVLS Requirement.

Industry Context

Femasys operates in the women's health sector, specifically focusing on biomedical innovations for significant unmet needs. The company's product portfolio, including infertility treatments and permanent birth control solutions, aims to offer non-surgical, in-office alternatives to traditional methods, potentially disrupting multi-billion dollar global market segments that have seen limited advancement. This positions Femasys as a player seeking to provide safer, more accessible, and lower-cost solutions compared to existing pharmaceutical, implant, or surgical options.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The company's convertible notes payable, net, include amounts related to related parties.
• In the May 2025 Private Placement, certain directors and officers purchased an aggregate of 98,040 shares at a per share price equal to $1.02.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience significant dilution from the new offering. The ongoing Nasdaq delisting risk poses a threat to the liquidity and value of their investment. The 'going concern' warning indicates potential for further value erosion.
• **New Investors**: Will face immediate and substantial dilution. Their investment is subject to high volatility and the risk of delisting.
• **Employees**: The company's ability to continue as a going concern and secure additional financing directly impacts job security and future growth opportunities.
• **Customers**: Continued product development and commercialization efforts, supported by the capital raise, could lead to new or improved women's health solutions.
• **Creditors**: The maturity of convertible notes in November 2025 and the 'going concern' warning highlight potential risks to repayment, though the capital raise may provide some short-term relief.

Next Steps

• Regain compliance with Nasdaq's Minimum MVLS Requirement by November 17, 2025.
• Regain compliance with Nasdaq's Minimum Bid Price Requirement by January 12, 2026.
• Continue U.S. clinical development and enrollment for FemBloc permanent birth control.
• Further commercialization efforts for FemaSeed in the U.S. and FemBloc in the European Union.
• Monitor and potentially utilize the Equity Line of Credit with Alumni Capital LP.
• Consider options to regain Nasdaq compliance, including a reverse stock split.

Key Dates

Recommendation

The filing reveals severe financial distress, including an explicit 'going concern' warning from auditors and two active Nasdaq delisting notices for failing to meet both market value and minimum bid price requirements. While the public offering aims to raise capital, it comes with substantial immediate dilution for new investors and does not fundamentally resolve the underlying profitability issues or guarantee Nasdaq compliance. The company's convertible notes mature in November 2025, adding further financial pressure. Despite some positive product developments, the overwhelming financial and operational risks make this a highly speculative investment with significant downside potential. A seasoned investor would likely seek to exit or avoid this stock given the high probability of further value erosion or delisting.

Keywords

Femasys, Women's Health, Biomedical, Medical Device, Infertility Treatment, Birth Control, FemBloc, FemaSeed, Nasdaq Listing, Public Offering, SEC S-1, Capital Raise, FDA Approval, CE Mark, Clinical Trials, Dilution, Going Concern